tradingkey.logo

scPharmaceuticals Inc

SCPH
5.670USD
0.000
終値 11/07, 16:00ET15分遅れの株価
302.16M時価総額
損失額直近12ヶ月PER

scPharmaceuticals Inc

5.670
0.000

詳細情報 scPharmaceuticals Inc 企業名

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

scPharmaceuticals Incの企業情報

企業コードSCPH
会社名scPharmaceuticals Inc
上場日Nov 17, 2017
最高経営責任者「CEO」Mr. John H. Tucker
従業員数162
証券種類Ordinary Share
決算期末Nov 17
本社所在地25 Burlington Mall Road, Suite 203
都市BURLINGTON
証券取引所NASDAQ Global Select Consolidated
United States of America
郵便番号01803
電話番号16175170730
ウェブサイトhttps://www.scpharmaceuticals.com/
企業コードSCPH
上場日Nov 17, 2017
最高経営責任者「CEO」Mr. John H. Tucker

scPharmaceuticals Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--

収益内訳

データなし
データなし
事業別
地域別
データなし

株主

更新時刻: Fri, Nov 7
更新時刻: Fri, Nov 7
株主統計
種類
株主統計
株主統計
比率
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
8.57%
Lytton (Laurence W)
5.49%
Lundbeckfond Invest
5.34%
Glazer Capital, LLC
4.61%
他の
64.71%
株主統計
株主統計
比率
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
8.57%
Lytton (Laurence W)
5.49%
Lundbeckfond Invest
5.34%
Glazer Capital, LLC
4.61%
他の
64.71%
種類
株主統計
比率
Investment Advisor
21.37%
Hedge Fund
19.70%
Private Equity
12.33%
Investment Advisor/Hedge Fund
8.20%
Individual Investor
5.85%
Research Firm
3.74%
Venture Capital
2.30%
Bank and Trust
0.14%
Insurance Company
0.02%
他の
26.36%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
203
36.40M
67.81%
-13.56M
2025Q2
207
43.86M
83.06%
-9.87M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
2023Q2
160
30.81M
85.97%
-2.10M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
OrbiMed Advisors, LLC
6.06M
11.29%
--
--
Jun 30, 2025
Rubric Capital Management LP
4.60M
8.57%
-173.02K
-3.62%
Jun 30, 2025
Lytton (Laurence W)
2.94M
5.49%
+1.12M
+61.35%
Sep 30, 2024
Lundbeckfond Invest
2.86M
5.34%
+2.86M
--
Sep 30, 2024
Glazer Capital, LLC
2.47M
4.61%
+2.47M
--
Sep 02, 2025
The Vanguard Group, Inc.
1.84M
3.42%
-157.11K
-7.88%
Jun 30, 2025
Luther King Capital Management Corp.
3.54M
6.6%
+420.00K
+13.46%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.99M
3.7%
-164.72K
-7.65%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.66M
3.1%
+13.12K
+0.80%
Jun 30, 2025
5AM Ventures
1.20M
2.24%
--
--
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Invesco NASDAQ Future Gen 200 ETF
0.5%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
詳細を見る
Invesco NASDAQ Future Gen 200 ETF
比率0.5%
iShares Micro-Cap ETF
比率0.04%
ProShares Ultra Nasdaq Biotechnology
比率0.03%
Invesco Nasdaq Biotechnology ETF
比率0.03%
Global X Russell 2000 ETF
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
iShares Russell 2000 Growth ETF
比率0.01%
iShares Russell 2000 ETF
比率0.01%
ProShares UltraPro Russell2000
比率0.01%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI